Literature DB >> 9198203

Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion.

H Sato1, Y Okada, M Seiki.   

Abstract

Activated gelatinase A is reportedly associated with tumor spread. We identified a novel matrix metalloproteinase that localizes on the cell surface and mediate the activation of progelatinase A. Thus, this progelatinase A activator was named membrane-type matrix metalloproteinase (MT1-MMP). Following the first-discovery of MT1-MMP, two other MT-MMPs which can activate progelatinase A were identified (MT2- and MT3-MMP, respectively). Among these three MT-MMPs, MT1-MMP is most often overexpressed in malignant tumor tissues, including lung and stomach carcinomas that contain activated gelatinase A. This suggests that MT1-MMP is most closely associated with the activation of progelatinase A in these tumor tissues. The expression of MT1-MMP also induced binding of gelatinase A to the cell surface by functioning as a receptor. The cell surface localization of proteinases has advantages over pericellular proteolysis. MT1-MMP and its family may play a central role in the cell surface localization and activation of progelatinase A and via this mechanism, tumor cells use exogenous progelatinase A to mediate the proteolysis associated with invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9198203

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

1.  Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells.

Authors:  B Annabi; A Pilorget; N Bousquet-Gagnon; D Gingras; R Béliveau
Journal:  Biochem J       Date:  2001-10-15       Impact factor: 3.857

Review 2.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

Review 3.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

Review 4.  Localizing matrix metalloproteinase activities in the pericellular environment.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  FEBS J       Date:  2010-11-19       Impact factor: 5.542

5.  Matrix metalloproteinase-1 promotes muscle cell migration and differentiation.

Authors:  William Wang; Haiying Pan; Kiley Murray; Bahiyyah S Jefferson; Yong Li
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

6.  Differential effects of shear stress and cyclic strain on Sp1 phosphorylation by protein kinase Czeta modulates membrane type 1-matrix metalloproteinase in endothelial cells.

Authors:  Ji Il Kim; Alfredo C Cordova; Yo Hirayama; Joseph A Madri; Bauer E Sumpio
Journal:  Endothelium       Date:  2008 Jan-Feb

7.  Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.

Authors:  László Herszényi; Ferenc Sipos; Orsolya Galamb; Norbert Solymosi; István Hritz; Pál Miheller; Lajos Berczi; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

8.  Temporal gene expression profiling during rat femoral marrow ablation-induced intramembranous bone regeneration.

Authors:  Joel K Wise; Kotaro Sena; Karen Vranizan; Jacob F Pollock; Kevin E Healy; W Frank Hughes; D Rick Sumner; Amarjit S Virdi
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

9.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

Review 10.  Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms.

Authors:  A Albini
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.